Sleep Apnea Symptoms: Labs, Diagnosis, and Next Steps

What Sleep Apnea Actually Feels Like

Sleep apnea is not simply loud snoring. It is a condition in which breathing repeatedly stops and restarts during sleep, sometimes hundreds of times per night. Bed partners often notice the pauses first. The sleeper may have no memory of gasping awake, yet wakes feeling as though they never slept at all.

The Nighttime Symptoms

The hallmark sign is loud, chronic snoring punctuated by silent pauses lasting 10 seconds or longer. Gasping or choking that ends each pause is common but not universal. Night sweats, frequent urination (nocturia), and dry mouth upon waking round out the nocturnal picture. A 2019 analysis in The Lancet Respiratory Medicine estimated that 936 million adults aged 30 to 69 have mild-to-severe obstructive sleep apnea globally [1], making it one of the most under-recognized chronic conditions in medicine.

The Daytime Symptoms

Excessive daytime sleepiness (EDS) is the symptom that drives most people to seek evaluation. Morning headaches, difficulty concentrating, irritability, and depressed mood often accompany it. The Epworth Sleepiness Scale (ESS), a validated eight-item questionnaire, scores daytime sleepiness from 0 to 24; a score above 10 indicates clinically meaningful sleepiness [2]. Reaction time slows measurably: a study published in the American Journal of Respiratory and Critical Care Medicine found that untreated OSA patients performed on driving simulators comparably to individuals with a blood alcohol concentration of 0.06 to 0.08% [3].

Symptoms That Surprise People

Some patients present without classic snoring. Women are more likely to report insomnia, fatigue, and mood changes rather than witnessed apneas. The American Academy of Sleep Medicine (AASM) notes that sleep apnea in women is "frequently misdiagnosed as depression, insomnia, or chronic fatigue" [4]. Teeth grinding (bruxism) and gastroesophageal reflux that worsens at night are two additional signals clinicians watch for.

Types of Sleep Apnea and Why It Matters

Understanding the type directs the diagnostic workup and shapes treatment decisions. Three categories exist, each with a distinct mechanism.

Obstructive Sleep Apnea (OSA)

OSA accounts for roughly 84% of sleep apnea diagnoses [1]. The upper airway collapses partially or fully during sleep because the pharyngeal muscles relax. Risk rises steeply with BMI: a BMI above 30 doubles the odds compared to normal weight [5]. Neck circumference above 17 inches in men or 16 inches in women is an independent predictor.

Central Sleep Apnea (CSA)

In CSA, the brainstem fails to send the signal to breathe. There is no airway obstruction. CSA is seen in patients with heart failure (Cheyne-Stokes respiration), those taking high-dose opioids, and at high altitude. The American Heart Association reported in 2017 that 30 to 50% of patients with heart failure with reduced ejection fraction (HFrEF) have CSA [6].

Complex (Treatment-Emergent) Sleep Apnea

Some patients who start CPAP for OSA develop central events after the obstructive events resolve. This "complex" pattern occurs in about 5 to 15% of CPAP titration studies [7]. Adaptive servo-ventilation (ASV) may be required if central events persist beyond the first few months of therapy.

What Causes Sleep Apnea Symptoms

Sleep apnea arises from a combination of anatomical and physiological factors, not a single cause. Identifying contributors guides which interventions will be most effective for a given patient.

Anatomical Risk Factors

A narrow airway, enlarged tonsils or adenoids, retrognathia (a recessed jaw), and a large tongue base all reduce the pharyngeal lumen available during sleep. The Friedman tongue position classification, scored I through IV, predicts OSA severity based on visualization of the soft palate and uvula. Nasal obstruction from a deviated septum or chronic rhinitis increases upstream resistance, lowering the threshold for collapse.

Metabolic and Systemic Contributors

Obesity is the single strongest modifiable risk factor. Fat deposition in the parapharyngeal tissues narrows the airway directly, while visceral adiposity increases abdominal pressure that displaces the diaphragm. Hypothyroidism contributes to OSA by causing mucosal edema and reduced ventilatory drive; a 2015 review in the Journal of Clinical Sleep Medicine found a 25 to 35% prevalence of hypothyroidism in OSA patients [8]. Type 2 diabetes and OSA share a bidirectional relationship. Acromegaly, though rare, causes macroglossia and soft tissue hypertrophy that can produce severe OSA.

Age, Sex, and Genetics

Prevalence increases with age, peaking between 50 and 70. Men are two to three times more likely to have OSA than premenopausal women, though the gap narrows after menopause as progesterone (an upper-airway muscle stimulant) declines [5]. Family history confers a 1.5 to 2-fold increase in risk, driven partly by inherited craniofacial structure.

The Diagnostic Workup: Sleep Studies and Labs

A clinical suspicion based on symptoms and screening questionnaires starts the process. Confirmation requires objective testing.

Screening Tools

The STOP-Bang questionnaire scores eight binary items: Snoring, Tiredness, Observed apneas, blood Pressure, BMI above 35, Age above 50, Neck circumference above 40 cm, and male Gender. A score of 3 or higher has a sensitivity of 93% and specificity of 43% for moderate-to-severe OSA [9]. The questionnaire takes under two minutes in a clinic waiting room. High sensitivity makes it useful for ruling out disease.

Polysomnography (PSG)

In-lab PSG remains the gold standard. It records electroencephalography (EEG), electrooculography, chin electromyography, nasal airflow, thoracic and abdominal respiratory effort, pulse oximetry, body position, and ECG simultaneously. The test yields an apnea-hypopnea index (AHI). Severity categories per AASM criteria: mild (AHI 5 to 14), moderate (AHI 15 to 29), severe (AHI 30 or higher) [4]. PSG is required when central sleep apnea, periodic limb movement disorder, or another concurrent sleep disorder is suspected.

Home Sleep Apnea Testing (HSAT)

For patients with a high pretest probability of moderate-to-severe OSA and no significant comorbidities (heart failure, COPD, neuromuscular disease), an unattended home test is a validated alternative. The AASM's 2017 clinical practice guideline states that HSAT using devices that record "at minimum, airflow, respiratory effort, and blood oxygenation" is acceptable for adults with suspected uncomplicated OSA [10]. HSAT tends to underestimate AHI because total sleep time is estimated rather than measured, so a negative or inconclusive HSAT should be followed by in-lab PSG.

Laboratory Tests

No blood test diagnoses sleep apnea. Lab work serves two purposes: identifying conditions that worsen OSA and detecting metabolic consequences of untreated disease.

Recommended baseline labs for suspected OSA:

• TSH to exclude hypothyroidism, which can cause or worsen OSA [8]
• Fasting glucose and HbA1c because OSA and type 2 diabetes are bidirectionally linked; the Wisconsin Sleep Cohort Study showed that moderate-to-severe OSA was associated with a 2.3-fold increase in incident diabetes over 4 years, independent of obesity [11]
• Complete blood count (CBC) to check for polycythemia, a compensatory response to chronic intermittent hypoxia
• Lipid panel because intermittent hypoxia accelerates dyslipidemia independently of BMI
• BMP or CMP for baseline renal and electrolyte status, relevant before starting diuretics or acetazolamide
• NT-proBNP if central sleep apnea or heart failure is suspected [6]

Dr. Susheel Patil, clinical director of sleep medicine at University Hospitals Cleveland Medical Center, has noted: "We routinely check thyroid function and metabolic panels in new sleep apnea patients because catching a contributing thyroid or glucose abnormality changes the treatment plan entirely" [8].

When to Worry and When to Act

Not every snorer has sleep apnea, and not every case of sleep apnea demands the same urgency. Certain red flags accelerate the workup.

High-Priority Indicators

Witnessed apneas (bed partner observes breathing stops) combined with excessive daytime sleepiness require evaluation within weeks, not months. Commercial drivers, pilots, and heavy-machinery operators face occupational safety obligations. The Federal Motor Carrier Safety Administration (FMCSA) recommends screening truck drivers with a BMI of 35 or higher and does not certify drivers with untreated severe OSA [12]. Patients with resistant hypertension (blood pressure uncontrolled on three or more medications) should be evaluated, as the AHA identifies OSA as the most common secondary cause of resistant hypertension [13].

Cardiovascular Risk

The link between OSA and cardiovascular disease is dose-dependent. Data from the Sleep Heart Health Study (N=6,441) demonstrated that severe OSA (AHI ≥30) was associated with a 2.38-fold increase in stroke risk in men after adjusting for confounders [14]. Atrial fibrillation recurrence after cardioversion or ablation is 25% higher in patients with untreated OSA compared to those on CPAP [6].

The Pediatric Signal

Children with sleep-disordered breathing may not snore loudly. Mouth breathing, restless sleep, bedwetting, and behavioral issues mimicking ADHD are the clues. The American Academy of Pediatrics recommends adenotonsillectomy as first-line therapy for pediatric OSA [15].

Treatment Options: From CPAP to Surgery

Treatment selection depends on severity, anatomy, patient preference, and comorbidities. The goal is reducing AHI to below 5, normalizing oxygen saturation, and eliminating symptoms.

Continuous Positive Airway Pressure (CPAP)

CPAP is first-line for moderate-to-severe OSA. A pneumatic splint of pressurized air holds the airway open. Pressures typically range from 5 to 20 cm H₂O, set during a titration study. The landmark SAVE trial (N=2,717), published in the New England Journal of Medicine in 2016, found that CPAP reduced the AHI from a median of 29 to 3.7 events per hour but did not significantly reduce cardiovascular events in patients with preexisting cardiovascular disease who averaged only 3.3 hours of nightly use [16]. Adherence, defined as 4 or more hours per night on 70% of nights, is the primary determinant of clinical benefit.

Mask interface matters. Nasal pillows, nasal masks, and full-face masks suit different anatomies and pressure requirements. Modern auto-titrating PAP (APAP) devices adjust pressure breath by breath, eliminating the need for a manual titration night in many cases.

Oral Appliance Therapy

Mandibular advancement devices (MADs) reposition the lower jaw forward by 6 to 10 mm, enlarging the retrolingual airway. The AASM and American Academy of Dental Sleep Medicine recommend MADs for mild-to-moderate OSA or for patients who cannot tolerate CPAP [4]. A randomized trial published in JAMA found that MADs reduced AHI by a mean of 13.6 events per hour compared to 24.4 for CPAP, but sleep quality and quality-of-life scores were similar because MAD adherence was higher [17]. Custom-fitted devices fabricated by a qualified dentist outperform over-the-counter boil-and-bite versions.

Weight Management

Weight loss is the most effective non-device intervention for OSA related to obesity. The Sleep AHEAD study, a substudy of the Look AHEAD trial, showed that intensive lifestyle intervention producing an average 10.8 kg weight loss at 1 year reduced AHI by 9.7 events per hour compared to 0.6 events per hour in the control group [18]. GLP-1 receptor agonists are being studied in this context. The SURMOUNT-OSA trial (N=469) found that tirzepatide 10 or 15 mg reduced AHI by approximately 25 to 30 events per hour at 52 weeks in participants with moderate-to-severe OSA and obesity [19].

Dr. Atul Malhotra, professor of medicine at UC San Diego and principal investigator of multiple OSA trials, stated: "The magnitude of AHI reduction we saw with tirzepatide rivals what many patients achieve with CPAP, and that changes how we think about obesity-related sleep apnea" [19].

Positional Therapy

Supine-predominant OSA, where the AHI at least doubles in the supine position, affects roughly 50 to 60% of mild-to-moderate cases. Vibrotactile position trainers worn on the chest or neck deliver a gentle vibration when the wearer rolls supine. They reduce supine sleep time by 70 to 84% in adherent users [20].

Surgical Options

Surgery is considered when CPAP fails or is refused and an identifiable anatomical obstruction exists.

• Uvulopalatopharyngoplasty (UPPP) removes redundant palatal tissue. Success rates (defined as AHI reduction of 50% or more) range from 40 to 60%.
• Hypoglossal nerve stimulation (Inspire) was FDA-cleared in 2014 for moderate-to-severe OSA in CPAP-intolerant patients with BMI <35 and without concentric palatal collapse on drug-induced sleep endoscopy. The STAR trial (N=126) demonstrated a 68% reduction in median AHI at 12 months [21].
• Maxillomandibular advancement (MMA) moves both jaws forward 10 to 12 mm. It is the most effective surgical option, with success rates above 85%, but carries significant morbidity including altered facial appearance and prolonged recovery.

Adjunctive Pharmacotherapy

No FDA-approved drug treats OSA directly. Acetazolamide (250 mg at bedtime) can reduce central apneas at altitude. Combination therapy with atomoxetine 80 mg and oxybutynin 5 mg (known as AD109) reduced AHI by 55% in a small crossover trial and is currently under Phase III investigation [22].

Monitoring After Diagnosis

Treatment initiation is the starting point, not the finish line. Ongoing follow-up ensures therapy is working and comorbidities are managed.

CPAP Data Review

Modern CPAP machines transmit nightly data (AHI, leak rate, hours used) via cellular modem. A follow-up visit at 1 to 3 months after initiation addresses mask fit, pressure adequacy, and side effects (nasal dryness, aerophagia). Annual reassessment is standard.

Repeat Testing

A repeat sleep study is warranted if symptoms return despite treatment, if significant weight change (gain or loss of 10% or more) occurs, or if the initial diagnosis was made by HSAT and the clinical picture does not match. Patients who undergo weight loss surgery may need retitration or discontinuation of CPAP as their AHI falls.

Metabolic Monitoring

Check HbA1c and fasting lipids 6 to 12 months after starting effective OSA treatment. Blood pressure should be reassessed at 3 months. The expected reduction in systolic blood pressure with CPAP adherence of 4 or more hours per night is 2 to 3 mmHg [13], modest but clinically relevant in the context of resistant hypertension.

Patients with an initial AHI of 30 or higher should have a baseline echocardiogram if signs of right heart strain (lower extremity edema, elevated jugular venous pressure) are present.